Agilent is a global leader in life science, diagnostics, and analytical laboratory technologies. Now growing in the cell analysis space, Agilent instruments, software, services, solutions, and people provide trusted answers to our customers' most challenging questions.
What started as a unique offering of solutions focused on understanding cellular functionality based on underlying metabolic programming has transformed into a market-leading set of innovative tools with the additions of ACEA Biosciences and BioTek Instruments – providing customers the tools they need to uncover unique cell biology, discover novel drug targets, improve preclinical in vitro toxicology, and pioneer the next generation of immunotherapies.
Explore a breadth of solutions in real-time, impedance-based analysis of cell function, real-time cell metabolism, cell imaging and microscopy, microplate readers, microplate washers, flow cytometers, and more.
For Research Use Only. Not for use in diagnostic procedures.
Infectious disease research leads to the development of critical solutions to address past, present, and future infectious outbreaks— from revealing mechanism of host-pathogen effects and innate immune response, to more applied translational research on vaccine development and immune system function and autoimmune disease.
This live virtual event will showcase presentations by leading scientists from notable institutions around the world, sharing their research on infectious disease. Agilent, and BioTek, the newest member of the Agilent family, will be showcasing their latest innovations in cell analysis for infectious disease research including product launches, software demos, and scientific posters. Product experts from both companies will also be available to answer questions.
Discover how leading researchers worldwide are conducting novel research on infectious disease, and how Agilent provides key technologies to advance therapeutic opportunities relating to viral and microbial infection:
For Research Use Only. Not for use in diagnostic procedures.
Xiaoyu Zhang attained her Ph.D. in Cell Molecular and Development Biology from the University of California, Riverside, and received postdoctoral training at Sanford Burnham Prebys Medical Discovery Institute. Dr. Zhang is currently the senior research scientist at Agilent Technologies specializing in the development of applications for xCELLigence RTCA Cardio related instruments, leading cardiac safety screening programs and providing technical support for RTCA Cardio related systems.
Stéphane Pronost began his researcher's career in 1990 at the University of Caen (France) within the Laboratory of Biochemistry of Connective Tissue, developing molecular tools for cytokine expression studies in humans. He joined the Frank Duncombe Laboratory (France) with the mission of building up a R&D service in 1995. After having set-up PCR assays in different animal species, he focused on equine viral diseases and more lately on herpesvirus, equine arteritis equine influenza and Hepacivirus. His recent works concern EHV-1 and the different expression forms of its pathology, specifically EHV-1-associated myeloencephalopathy. His team has developed different study models for equine herpesviruses which have led recently to the isolation of a new strain of EHV-1 and the implementation of a screening protocol for antiviral molecules, based on RTCA technology. Since 2018 he manages the Impedancell Platform in a BSL-2 confinement (LABEO site, Impedancell Real-Time Cellular Activity - https://www.impedancell.fr/en ).
Dr Pronost gets involved in numerous training sessions on molecular biology since 1993 in the University of Caen and is furthermore an expert of the AFNOR group (French Agency for Standardisation) for PCR methods in Animal Health.). He has also been an auditor for the French Accreditation Committee (COFRAC) in molecular biology (animal health) since 2014.
Dr. Dankwa obtained her Ph.D. in Biological Sciences in Public Health at the Harvard T.H. Chan School of Public Health. Her doctoral research focused on the invasion of erythrocytes by malaria parasites, the first step in the establishment of malaria infection. Her studies identified a key pathway that restricts red blood cell invasion by Plasmodium knowlesi, a malaria parasite that naturally infects macaques but has caused outbreaks of human infections in Southeast Asia. Her findings help to understand zoonotic infections by P. knowlesi. She is currently a Postdoctoral Fellow at Seattle Children’s Research Institute, Center for Global Infectious Disease Research and a recipient of an American Heart Association (AHA) Postdoctoral Fellowship. Her work uncovered a potential mechanism by which binding of malaria parasites to blood vessels can disrupt the blood-brain barrier, resulting in brain swelling. Her current work aims to investigate the utility of kinase inhibitors in repairing a leaky blood-brain barrier as well as elucidating endothelial barrier dysfunction in cerebral malaria.
Heather is an Assistant Professor in the Department of Pediatrics and the Institute for the Study of Host-Pathogen Systems at the University of Tennessee Health Science Center. She is a cell biologist trained in biochemistry and infectious disease. She received her doctorate of philosophy in Biochemistry and Applied Environmental Toxicology through the University of Washington-Pacific Northwest National Laboratory Distinguished Graduate Research Program.
She did her postdoctoral training in immunology and virology under Drs Peter Doherty and Paul Thomas at St Jude Children's Research Hospital. Her current research focuses on defining the role of metabolism in respiratory viral infection and its regulation to identify meta-biomarkers for risk assessment and therapeutic targeting.
Brandon Lamarche received his Ph.D. in chemistry from Ohio State University, where his research focused on the chemistry and enzymology of DNA damage and repair, seeking to understand the ways in which organisms strike a balance between these two opposing processes to maintain their fitness, fuel their evolution, and defend themselves against pathogens. He subsequently worked as a postdoctoral fellow at the Salk Institute where he studied the biochemistry of DNA double strand break (DSB) repair, with particular emphasis on the type of DSBs generated by cancer chemotherapeutics. He now works as a principal scientist at Agilent Technologies where he focuses on developing real-time cell analysis applications using the xCELLigence platform. Currently, his two primary fields of interest are cancer immunotherapy and infectious diseases.
Côme Thieulent obtained his master's degree in science in 2016 from the University of Caen Normandie (France). Then he worked for a year at the Frank Duncombe laboratory (France) as an engineer and started working with RTCA technologies. Since 2017 Côme has been a doctoral student at the University of Caen (France) and works at the Frank Duncombe laboratory (France). He is currently in the last year of his doctorate. He uses xCELLigence technology throughout his doctoral work to identify new antiviral compounds to fight equine herpesvirus-1 (EHV-1). He had the opportunity to stay in the Dr Hans Nauwynck laboratory at the University of Ghent (Belgium) in order to develop innovative cell models for the study of EHV-1.
Kristen N. Peters Olson, Ph.D. is an Imaging Specialist and Field Applications Scientist for BioTek Instruments in the Greater Boston Area. She received her Ph.D. in Molecular Microbiology and Immunology and Pathobiology from the University of Missouri in 2012. Her dissertation focused on the Yersinia pestis effector protein, YopK, in modulating cell death modality during pneumonic plague. This in vivo infection model focused on the lung immune response to pneumonic plague and was performed in BSL3 conditions at the University of Missouri Laboratory for Infectious Disease Research. In her postdoctoral position at University of Massachusetts Medical School, she studied efferocytosis and its impact on the innate and adaptive immune response in the lung during tuberculosis. To broaden her infectious disease expertise, she accepted a postdoctoral position at the National Emerging Infectious Diseases Laboratories at Boston University, focused on Ebola, Marburg, and Lassa viruses. There, she collaborated with academic colleagues and industry leaders to develop a no-wash diagnostic assay based on SERS technology for the detection of hemorrhagic fever viruses in the field. With the onset of the Zika epidemic, she shifted her focus to Zika virus and developed a novel human placental explant model of infection to understand the cellular tropism, host response, and how the virus causes such severe impact to the developing fetus. This diverse background focusing on host-pathogen interaction in multiple disease models using a variety of assays prepared her for her current position. As an Imaging Specialist for BioTek Instruments, she assists researchers in learning automated imaging technology, developing protocols to best suit their needs, and providing suggestions to improve their research.
Kristin Bircsak is a Principal Scientist with MIMETAS, The Organ-on-a-Chip Company in Gaithersburg, Maryland. In 2016, she received her Ph.D. in Toxicology from Rutgers University following which she completed a postdoctoral fellowship at the University of Pennsylvania. In her training, Kristin utilized various model system to characterize the negative impact of drugs and environmental chemicals on reproduction and development. In her role at MIMETAS, Kristin drives the development of innovative 3D in vitro organotypic models and assays. Her research is centered on recapitulating the liver and prostate tumor microenvironment to aid in the accurate prediction of safe and effective candidate compounds.
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events